Stocks swiftly recovered from the DeepSeek-driven sell-off early in the week but came under pressure on Friday amid concerns ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Stocks closed the week slightly higher after Monday’s sell-off prompted by concerns over China’s DeepSeekopen-source API. In fact, the tech-heavy NASDAQ index was on pace to be the best-performing ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli Lilly and Palantir, as well as a key inflation metric from the Labor ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

President Donald Trump’s Medicare agency is seeking to bring more transparency to the US government’s drug price negotiation ...

Europe 'Must Fix' Weaknesses to Compete, EU's Von der Leyen Says EU nations must work together quickly to help the bloc compete against global economic powerhouses like China and the U.S., European ...